It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
Some thought this day would never arrive. After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B.
The company announced the great news after the market closed on Thursday. Dynavax stock jumped on Friday, adding to year-to-date gains of close to 470%. But with shares already soaring so much this year, is it too late to buy Dynavax stock now that Heplisav-B has won approval? I don't think so.
Image source: Getty Images.
Source: Fool.com
Dynavax Technologies Corp Stock
€10.70
1.050%
The community is currently still undecided about Dynavax Technologies Corp with 2 Buy predictions and 0 Sell predictions.
Based on the current price of 10.7 € the target price of 26 € shows a potential of 143.1% for Dynavax Technologies Corp which would more than double the current price.
